Complementary and alternative medicine in chronic liver disease

被引:186
作者
Seeff, LB
Lindsay, KL
Bacon, BR
Kresina, TF
Hoofnagle, JH
机构
[1] NIDDKD, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA
[2] Univ So Calif, Los Angeles, CA USA
[3] St Louis Univ, Sch Med, St Louis, MO 63103 USA
关键词
D O I
10.1053/jhep.2001.27445
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
CAM represents medical and health care practices that are not an integral part of conventional (Western) medicine. At least 42% of the general population and a similar proportion of liver disease patients use some form of CAM on a regular basis. Herbal preparations are used by 20% of liver disease patients, typically without the advice or even knowledge of their physician, the most common herb used being milk thistle or silymarin. Other candidate herbals for liver disease are glycyrrhizin, HM861, TJ-9, and Phyllanthus amarus. Many of these have been shown to protect against experimental liver injury in vivo, and most possess one or a combination of anti-oxidant, antifibrogenic, immune modulatory, or antiviral activities. None, however, have been shown to be effective in ameliorating the course of chronic liver disease in properly conducted RCTs. Current impediments to progress in developing reliable information on the safety and efficacy of botanicals are the incomplete understanding of their modes of action, the lack of standardization in their manufacture, and the complexity of the chemical ingredients in the average herbal extract.
引用
收藏
页码:595 / 603
页数:9
相关论文
共 83 条
[1]   Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature [J].
Anderson, IB ;
Mullen, WH ;
Meeker, JE ;
KhojastehBakht, SC ;
Oishi, S ;
Nelson, SD ;
Blanc, PD .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (08) :726-+
[2]   Alternative medicine - The risks of untested and unregulated remedies [J].
Angell, M ;
Kassirer, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (12) :839-841
[3]  
ARASE Y, 1997, CANCER, V79, P1491
[4]  
BACON BR, UNPUB HERBAL MED 861, P56
[5]  
BAOEN W, UNPUB EXPT CLIN STUD, P63
[6]   Is there any use for nontraditional or alternative therapies in patients with chronic liver disease? [J].
Bass N.M. .
Current Gastroenterology Reports, 1999, 1 (1) :50-56
[7]   Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C [J].
Batey, RG ;
Bensoussan, A ;
Fan, YY ;
Bollipo, S ;
Hossain, MA .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (03) :244-247
[8]   Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats [J].
Boigk, G ;
Stroedter, L ;
Herbst, H ;
Waldschmidt, J ;
Riecken, EO ;
Schuppan, D .
HEPATOLOGY, 1997, 26 (03) :643-649
[9]   Pharmacy and herbal medicine in the US [J].
Bouldin, AS ;
Smith, MC ;
Garner, DD ;
Szeinbach, SL ;
Frate, DA ;
Croom, EM .
SOCIAL SCIENCE & MEDICINE, 1999, 49 (02) :279-289
[10]   SILYBIN DIHEMISUCCINATE PROTECTS AGAINST GLUTATHIONE DEPLETION AND LIPID-PEROXIDATION INDUCED BY ACETAMINOPHEN ON RAT-LIVER [J].
CAMPOS, R ;
GARRIDO, A ;
GUERRA, R ;
VALENZUELA, A .
PLANTA MEDICA, 1989, (05) :417-419